Sequenom Posts 34 Percent Gain in Revenues for Q4; Stock Drops | GenomeWeb

This story has been updated from a previous version to include comments from Sequenom's earnings call.

NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market Thursday that its fourth quarter revenues climbed 34 percent from the fourth quarter of 2012, driven by sales of its MaterniT21 Plus test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.